Clarity Pharmaceuticals (ASX:CU6) reported Friday that its loss per diluted share in the fiscal first half widened to AU$0.074, compared to a loss of AU$0.066 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting a loss of AU$0.08 per share.
The company said it did not derive any revenue, as it does not have any commercial products.